Skip to main content

Table 2 Descriptive data of original articles reviewed

From: Clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular diseases—an updated systematic review

Year Authors Sample size Study design Outcome
2021 Wesley Tyler Abplanalp et al. [27] 10 Cohort • Presence of DNMT3A mutation in the monocytes of heart failure patients has increased the expression of inflammatory genes which might aid the provoke the occurrence of chronic heart failure.
2021 Michael C. Honigberg et al. [21] 19,606 Cohort • Association between natural premature menopause and CHIP = P = 0.001
• DNMT3A mutation was observed to be significantly associated with premature menopause
• Natural premature menopause might be considered as a risk signal for developing CHIP or CHIP-associated CVD
2021 Domingo A. Pascual-Figal et al. [24] 62 Cohort • Presence of DNMT3A or TET2 mutations might accelerate HF progression in terms of death (P = 0.008)
2020 Alexander G. Bick et al. [18] 97,691 Cohort • > 75% of CHIP mutations in DNMT3A, TET2, and ASXL1.
• 15% of CHIP mutations were in PPM1D, JAK2, SF3B1, SRSF2, and TP53
2020 Alexander G. Bick et al. [20] 35,416 Cohort • CHIP associated with increased CVD event risk (P = 0.019)
• Presence of large CHIP mutations adjusted for hSCRP value showed increase in CVD event risk (P = 0.0016)
• Presence of rs1880241 shows reduced CVD events in large CHIP carriers (P = 0.025)
• IL6R p.Asp358Ala allele reduces CVD event risk in individuals (p = 0.047)
2020 Wesley Tyler Abplanalp et al. [19] 17 Case-control • Patients with DNMT3A or TET2 CHIP mutations can be categorized for high risk for adverse outcomes of COVID-19
• SARS-CoV-2 patients could be tested for the presence of DNMT3A or TET2 CHIP-driver sequence variations to provide personalized treatment strategies such as IL-6 or IL-6R antagonists to mitigate CRS
2020 Lambert Busque et al. [26] 1887 Case-control • hs-CRP was significantly higher in CHIP carriers (P = 0.009)
• DNMT3A CHIP mutation carriers had higher hs-CRP (P = 0.04)
2020 Sebastian Cremer et al.25 419 Cohort Patients with two or more CHIP mutations have increased mortality risk (P <  0.001) as compared to patients with a single CHIP mutation or individuals without mutations. (P < 0.001).
2019 Lena Dorsheimer et al. [23] 200 CHF Cohort • DNMT3A ( 7% of patients); TET2 (4.5% of patients), KDM6A (2 % of patients), BCOR (1.5 % of patients)
• Significantly worse long-term clinical outcome observed in patients with DNMT3A/TET2mutations
2017 S. Jaiswal et al. [22] 8255 Case-control study The presence of CHIP mutation nearly doubled the risk of coronary heart disease in humans and mice with accelerated atherosclerosis.